论文部分内容阅读
目的:制备美洛昔康肠道内两次脉冲释药系统,并考察其体外释放影响因素。方法:以美洛昔康为模型药物,以欧巴代OY-P-7171为肠溶包衣、以EudragitNE30 D为延时脉冲包衣材料制备2种包衣片,用释放度测定法考察影响药物释放的因素。结果:组合制剂在人工胃液中不释放药物、在人工肠液中可以实现2次脉冲释药。释药时滞分别约为2和4 h。结论:服用美洛昔康组合片治疗风湿性关节炎,将给药后药物单次快速释药方式变成2次脉冲释药,不仅可减少胃刺激,而且能满足关节炎的时辰药理学治疗要求。
OBJECTIVE: To prepare two-time pulsatile drug delivery system for meloxicam in intestine and to investigate the influencing factors of in vitro release. Methods: Meloxicam was used as a model drug, and Opadry OY-P-7171 was enteric coated. Eudragit NE30 D was used as the delayed coating material to prepare two kinds of coated tablets. The influence of release was determined Drug release factors. Results: The combination preparation did not release the drug in the artificial gastric juice, and twice pulse release was achieved in the artificial intestinal juice. Drug release delays of about 2 and 4 h, respectively. Conclusion: The meloxicam combination tablets for the treatment of rheumatoid arthritis, will be administered after a single rapid drug release into a two-way pulse release, not only can reduce gastric irritation, but also to meet the time of arthritis pharmacological treatment Claim.